Cargando…

Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases

Diseases caused by chronic inflammation (e.g., arthritis, multiple sclerosis and diabetic ulcers) are multicausal, thus making treatment difficult and inefficient. Due to the age-associated nature of most of these disorders and the demographic transition towards an overall older population, efficien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hristodorov, Dmitrij, Mladenov, Radoslav, Huhn, Michael, Barth, Stefan, Thepen, Theo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475223/ https://www.ncbi.nlm.nih.gov/pubmed/23105975 http://dx.doi.org/10.3390/toxins4090676

Ejemplares similares

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo
por: Mladenov, Radoslav, et al.
Publicado: (2016)

CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases
por: Akinrinmade, Olusiji A., et al.
Publicado: (2017)

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo
por: Hristodorov, D, et al.
Publicado: (2013)

Human MAP Tau Based Targeted Cytolytic Fusion Proteins
por: Akinrinmade, Olusiji A., et al.
Publicado: (2017)

Selective elimination of inflammatory macrophages by Fcγ-RI-directed immunotoxins: a novel concept in the treatment of rheumatoid arthritis
por: van Roon, JAG, et al.
Publicado: (2002)

CD64 as a biomarker and therapeutic target in HAM/TSP and HTLV-1-associated Infective Dermatitis
por: Khouri, Ricardo, et al.
Publicado: (2011)

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.
por: Vooijs, W. C., et al.
Publicado: (1997)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model
por: Schiffer, S, et al.
Publicado: (2013)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin
por: Flavell, D J, et al.
Publicado: (2001)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19(+) tumors
por: Zheng, Qian, et al.
Publicado: (2017)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β–Expressing Macrophages
por: Furusho, Yuko, et al.
Publicado: (2012)

Systemic immunotoxin therapy of cancer: advances and prospects.
por: Wawrzynczak, E. J.
Publicado: (1991)

Antibody-Based Immunotoxins for Colorectal Cancer Therapy
por: Sanz, Laura, et al.
Publicado: (2021)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Abrin Immunotoxin: Targeted Cytotoxicity and Intracellular Trafficking Pathway
por: Gadadhar, Sudarshan, et al.
Publicado: (2013)

Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014)

Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer
por: Fleming, Bryan D., et al.
Publicado: (2016)

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Candidate targets for antibody therapy of rheumatoid arthritis: CD64 and IL-15
por: van de Winkel, J
Publicado: (2003)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

CD3-immunotoxin mediated depletion of T cells in lymphoid tissues of rhesus macaques
por: Wang, Lan, et al.
Publicado: (2023)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties
por: Kawakami, Koji, et al.
Publicado: (2006)

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
por: Vallera, Daniel A., et al.
Publicado: (2018)

In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
por: Hosseininejad-Chafi, Mohammad, et al.
Publicado: (2022)

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment
por: Narbona, Javier, et al.
Publicado: (2023)

Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma
por: Chavez-Cortez, Elda-Georgina, et al.
Publicado: (2019)

Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy
por: Polito, Letizia, et al.
Publicado: (2011)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

A Human Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in a Murine Transplantation Model
por: Gattenlöhner, S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h91vq25net8kahpeumgur1p4ar